Get the Daily Brief
Latest Biotech News
Parabilis pivots to an IPO to fund zolucatetide Phase 3
Parabilis Medicines filed IPO plans shortly after a Regeneron equity-and-upfront deal, signaling a funding push to advance its pipeline. In its SEC filing dated May 19, the company said IPO...
Capsida closes SYNRGY trial after cerebral edema death
Capsida Biotherapeutics said it has closed its SYNRGY Phase I/II gene therapy trial in STXBP1-related developmental and epileptic encephalopathy after a child death following infusion of CAP-002....
AI-and-accelerated computing partnership for Qiagen biomedical knowledge graphs
Qiagen said it is working with Nvidia to integrate accelerated computing and Nvidia’s BioNeMo platform into Qiagen Digital Insights’ curated biomedical knowledgebases. The aim is to increase the...
Immunotherapy and gene regulation via tau aggregates and z-RNA mechanism
A Nature Neuroscience study reports that tau aggregates can trigger neuronal death through a mechanism involving Z-RNA, offering a potential new target area for therapies in tauopathies....
Novel clinical and commercial diagnostic expansion: Diasorin GI syndromic PCR panel clearance
FDA cleared Diasorin’s Liaison Plex Gastrointestinal Flex Assay, a customizable syndromic GI pathogen PCR panel. Diasorin said the assay detects 24 pathogens across bacteria, viruses and...
Immunovant ends FcRn inhibitor program after phase 3 failures in eye disease
Immunovant said it will scrap its first-generation FcRn inhibitor after failing to meet efficacy endpoints in pair of Phase 3 eye disease trials. The company confirmed the program’s closure a...
Relay reports Phase 2 efficacy signal for zovegalisib in vascular anomalies
Relay Therapeutics reported a Phase 2 efficacy signal for zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies, reporting a 60% volumetric response. The company framed the...
AI system automates scientific discovery in lab-in-the-loop workflows
Nature reported work on “Robin,” a multi-agent system designed to automate more of the experimental biology workflow than prior AI tools. The system reportedly integrates literature-search agents...
Antibody-peptide conjugates move into discovery and funding
Regeneron and Parabilis Medicines launched a multi-target collaboration to create antibody–Helicon conjugates aimed at intracellular “undruggable” proteins. The partnership pairs Regeneron’s...
AI infrastructure for biomedical knowledgebases
Qiagen is expanding its digital drug-discovery tooling by integrating Nvidia accelerated computing and the Nvidia BioNeMo platform into Qiagen Digital Insights’ curated biomedical knowledgebases....
Clinical proof for infectious-disease and oncology diagnostics platforms
Diasorin received FDA 510(k) clearance for a customizable syndromic GI pathogen multiplex PCR panel for its Liaison Plex system. The Liaison Plex Gastrointestinal Flex Assay detects 24...
Cancer drug pipeline signals: PI3Kα inhibitor expands beyond breast cancer
Relay Therapeutics reported Phase 2 efficacy data for zovegalisib (RLY-2608) in patients with PIK3CA-driven vascular anomalies, reporting a 60% volumetric response. The company framed the readout...
Regulatory and governance shakeups at FDA and trial contracting bottlenecks
The EMA proposed a centralized contract-support platform and template framework aimed at reducing clinical trial start-up delays in Europe. The regulator cited stakeholder feedback that contract...
IPO and funding: creating cash runway for clinical development
A wave of biotech financing activity highlighted Parabilis’ IPO plans and Create Medicines’ Series B round to support its in vivo CAR-T mRNA platform. Parabilis, fresh off a Regeneron...
AI-first scientific discovery pipelines enter peer-reviewed validation
A peer-reviewed Nature report describes Robin, a multi-agent system that automates end-to-end experimental biology workflows—spanning hypothesis generation, experiment design, interpretation, and...
Alzheimer’s and neurodegeneration: mechanistic targets emerge
Alzheimer’s disease researchers reported a molecular mechanism that regulates amyloid plaque formation by controlling BACE1 through the protein FBXW7α. The study, published in Cell Death Discovery...
Neonatal and pediatric care risk stratification improves with biomarkers and tools
Research aimed at improving neonatal and pediatric outcomes highlighted both biomarker discovery and clinical tool evaluation. One study in Pediatric Research compared early-onset sepsis...
Ebola response accelerates as outbreak status escalates
WHO declared the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo a public health emergency of international concern, citing confirmation of the species and a high positivity...
Regulatory actions and major approvals
The FDA cleared Diasorin’s customizable multiplex gastrointestinal pathogen PCR panel, expanding the Liaison Plex Flex menu with a 24-pathogen assay that labs can narrow or broaden using Flex...
AI acceleration in drug discovery and lab automation
Qiagen and Nvidia announced an integration of accelerated computing and Nvidia’s BioNeMo into Qiagen Digital Insights’ curated biomedical knowledgebases, targeting faster, evidence-linked AI...